Ocular Therapeutix Chief Business Officer Namrata Saroj Sells $232K of Stock
Namrata Saroj, Chief Business Officer, sold 35,370 shares of Ocular Therapeutix, Inc at $6.55 a share, worth $232K in total on Nov 5, 2026. Shares held after the trade: 220,522 (-13.8%).
Ocular Therapeutix appointed Riad Sherif, M.D., to its Board of Directors as a Class I member, effective November 6, 2026. Dr. Sherif, currently the CEO of Oculis Holding AG and a former Alcon executive, received an initial equity grant of 88,000 stock options and 28,000 restricted stock units as part of his appointment.
Ocular Therapeutix reported a decrease in cash and cash equivalents to $530.6 million as of September 30, 2026, compared to $737.1 million at year-end 2025. Total assets decreased to $605.6 million, while total liabilities increased slightly to $164.7 million. The company is currently focused on Phase 3 clinical trials for AXPAXLI in wet AMD and NPDR.
Ocular Therapeutix reported Q3 2026 financial results, highlighting a cash position of $530.6 million and an expected runway into 2028. The company remains on track to submit its NDA for AXPAXLI in wet AMD during Q4 2026 following a positive pre-NDA meeting with the FDA in September.
Term
Q3 2026
“2026 has been a transformational year for Ocular Therapeutix and we are in a strong position as we prepare to submit our NDA for AXPAXLI in wet AMD under the 505(b)(2) regulatory pathway. Frequent injections define today’s wet AMD treatment experience, and we believe AXPAXLI has the transformative potential to drastically reduce the burden on patients and caregivers.”
Pravin U. Dugel, MD, Executive Chairman, President and CEO of Ocular Therapeutix